{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI was not estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"18.46","upperLimit":"NA","value":"25.33"},{"comment":"Upper limit of 95% CI was not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"17.45","upperLimit":"NA","value":"20.83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death due to any cause. Participants who were alive at the data cutoff date were censored for overall survival at their last contact date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received an oral dose of 45 milligram (mg) of MEK162 tablets (3 tablets of 15 mg) twice daily for each 28-day treatment cycle until disease progression, withdrawal of consent, initiation of subsequent anticancer therapy, lost to follow-up or death, whichever occurred first. Participants were followed up to 30 days after last dose of study intervention.","id":"OG000","title":"MEK162"},{"description":"Participants received chemotherapies as per treating physician's choice in accordance to the institutional standard of care. Participants received one of the three intravenous (IV) infusion therapies: Liposomal doxorubicin 40 milligram per meter square (mg/m\\^2) on Day 1 of each 28-day cycle or Paclitaxel 80 mg/m\\^2 on Days 1, 8, and 15 of each 28-day cycle or, Topotecan 1.25 mg/m\\^2 on Days 1 through 5 of each 21-day cycle. Participants were followed up to 30 days after last dose of study intervention.","id":"OG001","title":"Physician's Choice"}],"paramType":"MEDIAN","populationDescription":"Analysis population included all randomized participants as of PCD (201 participants in MEK162 group and 102 participants in physician's choice group). In the futility analysis based on PCD, the futility boundary was crossed, and therefore, no additional efficacy data was collected due to study early termination and no additional efficacy analyses were conducted.","reportingStatus":"POSTED","timeFrame":"From randomization date to the date of death, for censored participants at their last contact date (up to 24 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}